Prediction of prostate cancer progression by analysis of selected predictive parameters

US6025128A · kind A · utility

Assignees

• The University of Tulsa · US
• The John Hopkins University · US
• Cytodiagnostics, Inc. · US

Inventors

• Robert Veltri · Oklahoma City, US
• Michael Patrick Bacus · Seattle, US
• M. Craig Miller · Guthrie, US
• Kaveh Ashenayi · Tulsa, US
• Donald P. Coffey · Timonium, US
• Alan W. Partin · Baltimore, US
• Jonathan I. EPSTEIN · Baltimore, US

Key dates

• Filing date: Sep 29, 1994
• Grant date: Feb 15, 2000
• Expiry date: Sep 29, 2014

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S436/813
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

A method for screening individuals at risk for prostate cancer progression is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture factors, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict prostate cancer progression in patient samples.